Monday, 18 Mar 2019

You are here

Biologic High Out of Pocket Costs for Medicare Patients

Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern. 

A new Kaiser Family Foundation analysis examined the high out-of-pocket cost burden for Medicare enrollees taking specialty medications. For the majority of these medications, costs will occur above the catastrophic threshold, translating to $5444 in out-of-pocket costs in the catastrophic phase alone.

Specialty drugs account for nearly half of overall medicine spending and amount to more than 20% of total Part D spending.

They specifically calculated the expected annual 2019 out-of-pocket costs for 30 specialty tier drugs across 4 conditions: hepatitis C virus (HCV), multiple sclerosis (MS), cancer, and rheumatoid arthritis (RA). 

  • The annual out-of-pocket costs are expected to be higher in 2019 on average for 8 of the 10 specialty drugs (compared with 2016).
  • For 28 of the 30 specialty drugs covered by some or all plans, out-of-pocket costs in 2019 will average $8109.
  • Coverage varied widely for many of these specialty medications, reflecting a broad spectrum of out-of-pocket costs across the 4 conditions and 28 specialty tier drugs analyzed.
  • Patients taking cancer medications are most likely to face higher out-of-pocket costs in 2019 than other diseases, with out-of-pocket costs exceeding $8000, most of this spending is above the catastrophic threshold. 
  • Expected annual out-of-pocket costs for HCV medications exceed $2000, with the highest at $6338 for Harvoni.
  • Expected annual out-of-pocket costs in 2019 for MS range from $6507 for Avonex to $7409 for glatiramer acetate.
  • Expected annual out-of-pocket costs in 2019 for RA range from $4372 for Kevzara to $5471 for Humira.
  • For specialty tier drugs that are not covered, the authors estimated annual costs in Part D are at least 10 times higher than when covered.

Cubanski J, Koma W, Neuman T. The Out-of-Pocket Cost Burden for Specialty Drugs in Medicare Part D in 2019. Kaiser Family Foundation. 2019.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.